Global Bio-Clinical Trials 2012 Just Launched in India

            Global Bio-Clinical Trials 2012 Just Launched in India

  PR Newswire

  BANGALORE, July 11, 2012

BANGALORE, July 11, 2012 /PRNewswire/ --

Today, more and more countries across the globe are dedicated towards
developing a favourable environment for the growth of biopharmaceutical and
biosimilar products in their respective markets. The Indian regulatory bodies
like the DCGI and the ICMR too are constantly revising their norms and
standards to promote clinical trials, and eventually the growth of biotech
products in the country. This is largely due to the fact that these
bio-products are solutions to some of the most dreaded diseases and require
high manufacturing and marketing investments.

With these developments in the background, CPhI Conferences is launching
Global Bio-Clinical Trials 2012 , a highly anticipated strategic 4-day
initiative (25-28 September, Bangalore, India) focused on the challenges
pertaining to the conduct of clinical trials for the approval of sensitive
biopharmaceuticals and biosimilars drugs. An interactive seminar on 'Emerging
Market Regulations - Brazil, China, Russia, LATAM & Malaysia' will take place
on 25th September, and an exclusive workshop on
PharmacoKinetics/PharmacoDynamics studies on 28th September.

The 2-day conference (26-27 September) will provide solutions to dealing with
the current regulatory challenges and guidelines for robust design of clinical
trials, economic patient recruitment and retention protocols, latest tool and
techniques for clinical data management and medical writing, along with
updates on the latest pharmacovigilance trends.

Eminent speakers like Dr Ragunadarao Digumarti (HOD, Oncology, NIZAMS
Hyderabad), Mr Solomon Yimam (Assistant Director, Clinical research, US FDA),
Mr Scott Laufenberg (Assistant Director(BIMO),US FDA), Dr Arani Chatterjee
(VP, Clinical research, Panacea Biotec), Dr YK Gupta (National Scientific
Co-ordinator, Pharmacovigilance Programme of India), Dr Sanjeev Hegde (GM,
Clinical Development, Piramal Healthcare), Dr Goutam Pujari (VP, Clinical
Research Operations, Glenmark Pharmaceuticals), Dr Deven Parmar (CEO & Medical
Director, Karmic Life Sciences), Dr Ajay Gautam (Executive Director and Head
of Emerging Markets, AstraZeneca, China), Dr Sanish Davis (Director Clinical
Pharmacology in Emerging Markets, MSD), Mr Arjun Roy (Head CDM & Biometrics,
Ranbaxy) among other industry experts, are already on board to provide the
latest updates for development of biopharmaceuticals and biosimilars in their
respective organisations.

Global Bio-Clinical Trials 2012 will bring together 100+ regulators, heads of
clinical research, clinical operations & clinical R&D, pharmacovigilance,
medical affairs, clinical data management and medical doctors from across
biopharmaceutical and biosimilars companies across India and the world, to
help increase awareness about the latest developments pertaining to clinical
trials of bio-products. For more details log on to
www.bioclinicaltrials.com/pr

About CPhI India:

CPhI India is a UBM brand, and is the largest and most important meeting place
for the Indian pharma industry. Each year CPhI attracts around 850 exhibitors
and 30,000 visitors to the show, providing us with an unrivalled reach to all
the key decision makers in the Indian Pharma industry. For more information,
visit conferences-india@ubm.com

About UBM India:

UBM India is a subsidiary of UBM plc, which is the second largest independent
exhibition organiser in the world. It is the largest trade exhibition
organiser in India, responsible for 26 exhibitions in different locations
across the country. The company is also involved in the organisation of
conference programmes throughout India and in the publications of trade
journals and magazines. For further details, visit http://www.ubmindia.in .

Primary Media Contact: Asan Bano, conferences-india@ubm.com ,
asan.bano@ubm.com  91-22-40461466, 91-22-66122602

Contact: PRN